We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




First Ever Molecular Diagnostic Tool Could Enable Early Diagnosis of Inflammatory Diseases in Children

By LabMedica International staff writers
Posted on 11 Sep 2024

Inflammatory diseases pose a particular threat to children, as symptoms like fever and rash are often nonspecific, leading to frequent misdiagnoses. Conditions like Multisystem Inflammatory Syndrome in Children (MIS-C) can cause inflammation in vital organs such as the heart, lungs, and brain if not promptly treated. Similarly, Kawasaki disease (KD), the leading cause of acquired heart disease in children, can result in cardiac aneurysms and heart attacks. Now, a new cell-free RNA-based test could become the first molecular diagnostic tool to help clinicians detect these inflammatory conditions in children at an early stage.

Cell-free RNA, which is released into the bloodstream through cell death or active secretion, has been harnessed by a research collaboration led by Cornell University (Ithaca, NY, USA). The team developed machine learning models that utilize these molecular RNA fragments to diagnose complex pediatric inflammatory conditions. This diagnostic tool can accurately distinguish between Kawasaki disease, MIS-C, viral infections, or bacterial infections, while also monitoring the patient’s organ health. These results, published in the Proceedings of the National Academy of Sciences, build on earlier work that began four years ago, focusing on severe cases of COVID-19 and MIS-C in children, which surged during the pandemic.

Initially, the researchers were investigating the potential of cell-free DNA in studying these diseases, but their focus shifted to cell-free RNA due to the wealth of information it provides. While cell-free RNA has already been identified as a valuable biomarker for pregnancy and cancer, it is far less studied than cell-free DNA. The research team analyzed 370 plasma samples from pediatric patients with various inflammatory conditions. They converted the RNA to DNA and then used DNA sequencing to explore the protein-coding regions of the genome. The team spent a year refining machine learning algorithms to identify disease signatures in the samples, effectively creating a suite of tools to interpret the cell-free RNA data. In addition to developing an accurate diagnostic model, the researchers demonstrated that cell-free RNA sequencing could also be used to assess damage to specific tissues and organs, including the heart, liver, nervous system, endothelium, and upper respiratory tract.

“When you analyze RNA in plasma, what you’re looking at is RNA from dying cells, and also RNA that’s been released from cells anywhere in the body,” said lead author Conor Loy. “This gives you a huge advantage. In inflammatory conditions, there’s lots of cell death. Cells are, in some cases, exploding and their RNA gets released into plasma. By isolating that RNA and sequencing it, we can discover biomarkers for disease and backtrack where the RNA is coming from to measure cell death.”

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Immunofluorescence Analyzer
MPQuanti
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.